Use of whole genome sequencing to identify low-frequency mutations in COVID-19 patients treated with remdesivir
Nirmalarajah, K.; Maguire, F.; Yim, W.; Aftanas, P.; Li, A. X.; Shigayeva, A.; Yip, L.; Zhong, X. Z.; McGeer, A. J.; Mubareka, S.; Kozak, R.
Show abstract
BackgroundWe investigate the effects of remdesivir (RDV) treatment on intra-host SARS-CoV-2 diversity and low-frequency mutations in moderately ill hospitalized COVID-19 patients and compare them to patients without RDV treatment. MethodsSequential collections of nasopharyngeal and mid-turbinate swabs were obtained from 16 patients with and 31 patients without RDV treatment. A total of 113 samples were sequenced and mutation analyses were performed. ResultsWe did not identify any drug resistant mutations during RDV therapy. In genes encoding and associated with the replication complex, low-frequency minority variants that do not reach fixation within the sampling period were detected in 6/16 (37.5%) and 14/31 (45%) patients with and without RDV treatment respectively. We did not detect significant differences in within-host diversity and positive selection between the RDV-treated and untreated groups. ConclusionsMinimal intra-host variability and stochastic low-frequency variants detected in moderately ill patients suggests little selective pressure in patients receiving short courses of RDV. Patients undergoing short regimens of RDV therapy should continue to be monitored.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.